Application
Immunofluorescence staining of methanol-fixed Hela cells using BCL-2 Antibody .Application
Western blot analysis of extracts from Hela, A2780 and 293 cells using BCL-2 Antibody .Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using BCL-2 Antibody (left) or the same antibody preincubated with blocking peptide (right).| Product Name | Bcl-2 antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit polyclonal antibody to Bcl-2Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). |
| Immunogen | Peptide sequence around aa. 54~58 (G-H-T-P-H) derived from Human BCL-2. |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | ICC/IFIHC-PWB |
| Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100, ICC/IF: 1:100~1:200. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml (Please refer to the vial label for the specific concentration) |
| Purification | Affinity purified |
| Gene Synonyms | Bcl-2 BCL2 protein phosphatase 1 regulatory subunit 50 apoptosis regulator Bcl-2 B-cell CLL/lymphoma 2 |
|---|---|
| Target | Bcl-2 |
| Molecular Weight(MW) | 26 (note) |
Application
Immunofluorescence staining of methanol-fixed Hela cells using BCL-2 Antibody .
Application
Western blot analysis of extracts from Hela, A2780 and 293 cells using BCL-2 Antibody .
Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using BCL-2 Antibody (left) or the same antibody preincubated with blocking peptide (right).| Application Notes | Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100, ICC/IF: 1:100~1:200. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
